Brown E M, Pollak M, Hebert S C
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Annu Rev Med. 1998;49:15-29. doi: 10.1146/annurev.med.49.1.15.
The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from parathyroid, kidney and other cell types has clarified the mechanisms through which Ca2+o exerts its direct actions on various cells and tissues. In the parathyroid, the CaR mediates the inhibitory effects of Ca2+o on parathyroid hormone (PTH) secretion and likely on expression of the PTH gene and parathyroid cellular proliferation. In the kidney, the receptor mediates direct inhibition of the reabsorption of divalent cations in the cortical thick ascending limb, and it likely underlies the inhibitory actions of hypercalcemia on the urinary-concentrating mechanism in the medullary thick ascending limb and inner medullary collecting duct. The identification of inherited diseases of Ca2+o-sensing that arise from mutations in the CaR gene has proven, by genetic means, the central role of the CaR in mineral ion homeostasis and the importance of the receptor in regulating the parathyroid and kidney. An allosteric CaR agonist ("calcimimetic") is currently being tested for the treatment of primary hyperparathyroidism, and CaR-based therapeutics will likely be applicable to other disorders in which CaRs are under- or overactive. Thus the discovery of the CaR and its associated diseases has documented that Ca2+o plays an essential role as an extracellular first messenger, in addition to serving its better recognized role as an intracellular second messenger.
最近从甲状旁腺、肾脏及其他细胞类型中克隆出细胞外钙(Ca2+o)敏感受体(CaR),这阐明了Ca2+o对各种细胞和组织发挥直接作用的机制。在甲状旁腺中,CaR介导Ca2+o对甲状旁腺激素(PTH)分泌的抑制作用,可能还介导对PTH基因表达及甲状旁腺细胞增殖的抑制作用。在肾脏中,该受体介导对皮质厚升支中二价阳离子重吸收的直接抑制,高钙血症对髓质厚升支和内髓集合管尿液浓缩机制的抑制作用可能也与之有关。通过基因手段证实,由CaR基因突变引起的遗传性Ca2+o感知疾病证明了CaR在矿物质离子稳态中的核心作用以及该受体在调节甲状旁腺和肾脏方面的重要性。一种变构CaR激动剂(“拟钙剂”)目前正在用于治疗原发性甲状旁腺功能亢进的试验,基于CaR的疗法可能适用于其他CaR活性不足或过强的疾病。因此,CaR及其相关疾病的发现证明,Ca2+o除了作为细胞内第二信使发挥其广为人知的作用外,还作为细胞外第一信使发挥着重要作用。